膀胱癌(BLCA)是一种常见的泌尿系统恶性肿瘤,与高复发率和不良预后相关。FAM111B,编码含有胰蛋白酶样半胱氨酸/丝氨酸肽酶结构域的蛋白质,与各种人类癌症的进展有关;然而,其参与BLCA的情况尚不清楚。在这项研究中,我们使用免疫组织化学研究了FAM111B基因在肿瘤组织中的表达与肿瘤旁组织相比,并观察到FAM111B基因在肿瘤组织中的表达明显更高。此外,临床特点分析显示,FAM111B基因表达增高与淋巴结转移相关,总生存率降低。为了研究它的功能作用,我们采用FAM111B敲低BLCA细胞模型并进行细胞增殖,伤口愈合,transwell,和流式细胞术测定。结果表明,FAM111B基因表达降低抑制了BLCA细胞的增殖和迁移,但诱导了细胞凋亡。体内实验进一步验证了FAM111B敲低抑制肿瘤生长。总的来说,我们的发现表明FAM111B在BLCA中充当癌基因,在肿瘤发生中起关键作用,programming,和BLCA的转移。总之,我们已经证明了FAM111B基因的表达与发育之间有很强的相关性,programming,和膀胱癌转移(BLCA)。因此,FAM111B是与BLCA相关的癌基因,有望作为未来治疗该癌症的分子靶标。
Bladder cancer (BLCA) is a prevalent malignancy of the urinary system, associated with a high recurrence rate and poor prognosis.
FAM111B, which encodes a protein containing a trypsin-like cysteine/serine peptidase domain, has been implicated in the progression of various human cancers; however, its involvement in BLCA remains unclear. In this study, we investigated the expression of
FAM111B gene in tumor tissues compared to para-tumor tissues using immunohistochemistry and observed a significantly higher FAM111B gene expression in tumor tissues. Furthermore, analysis of clinical characteristics indicated that the increased
FAM111B gene expression correlated with lymphatic metastasis and reduced overall survival. To investigate its functional role, we employed
FAM111B-knockdown BLCA cell models and performed cell proliferation, wound-healing, transwell, and flow cytometry assays. The results showed that decreased FAM111B gene expression inhibited proliferation and migration but induced apoptosis in BLCA cells. In vivo experiments further validated that
FAM111B knockdown suppressed tumor growth. Overall, our findings suggest that FAM111B acts as an oncogene in BLCA, playing a critical role in tumorigenesis, progression, and metastasis of BLCA. In conclusion, we have demonstrated a strong correlation between the expression of FAM111B gene and the development, progression, and metastasis of bladder cancer (BLCA). Thus, FAM111B is an oncogene associated with BLCA and holds promise as a molecular target for future treatment of this cancer.